Quarterly ResultApr 28, 2026, 05:03 PM
ASH Q2 Sales $482M, EPS $0.32; FY26 Guidance Updated
AI Summary
Ashland Inc. reported Q2 fiscal 2026 sales of $482 million, a 1% increase year-over-year, but net income fell to $16 million ($0.34 per diluted share) and Adjusted EBITDA decreased 9% to $98 million. Results were impacted by operational challenges at Calvert City and Hopewell, along with weather disruptions. The company updated its full-year fiscal 2026 sales guidance to $1,835-$1,870 million and Adjusted EBITDA guidance to $385-$400 million, citing slower productivity at Hopewell. Despite headwinds, Ashland generated strong cash flow and saw growth in Personal Care and resilient demand in Life Sciences.
Key Highlights
- Updated full-year fiscal 2026 sales guidance to $1,835-$1,870 million.
- Updated full-year fiscal 2026 Adjusted EBITDA guidance to $385-$400 million.
- Q2 sales were $482 million, up 1% from $479 million in prior-year quarter.
- Q2 net income was $16 million, or $0.34 per diluted share, down from $31 million.
- Q2 Adjusted EBITDA was $98 million, down 9% from $108 million.
- Q2 cash flows from operating activities were $50 million, up from $9 million.
- Life Sciences segment sales were $172 million, flat year-over-year.
- Personal Care segment sales increased 3% to $150 million.